Celsion (CLSN) jumps 12.9% after signing a technology development agreement for its ThermoDox...

Celsion (CLSN) jumps 12.9% after signing a technology development agreement for its ThermoDox liver-cancer treatment with China's Hisun, which will pay $5M upfront and manufacture the drug. The deal is a precursor to a China licensing agreement that could be worth hundreds of millions of dollars to Celsion, and comes ahead of the results of Phase III trials for ThermoDox. (PR)

Comments (5)
  • buyitcheap
    , contributor
    Comments (1902) | Send Message
    Wow. Hisun's pretty early on this.... they must have something on the Phase 3's to be that confident to put down that kind of call option.
    22 Jan 2013, 09:06 AM Reply Like
  • PeakOiler
    , contributor
    Comments (299) | Send Message
    Yeah, right. This is peanuts and a weak attempt by management to generate some positive PR. Only the data knows.
    22 Jan 2013, 09:15 AM Reply Like
  • buyitcheap
    , contributor
    Comments (1902) | Send Message
    22 Jan 2013, 09:19 AM Reply Like
  • jimmy J
    , contributor
    Comments (86) | Send Message
    There is no reason to think the data will not be positive as the research results to date have continually supported each phase , this agreement . Hisun will make the product and it will be used worldwide.
    22 Jan 2013, 09:53 AM Reply Like
  • begs
    , contributor
    Comments (8) | Send Message
    Agree, sounds a lot like hype
    22 Jan 2013, 10:40 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs